| Literature DB >> 34988330 |
Francesca Gatta1, Yama Haqzad2, Mahmoud Loubani2.
Abstract
BACKGROUND AND AIM: This study evaluates whether aortic valve replacement (AVR) or mitral valve replacement (MVR) with biological versus mechanical prostheses is independent risk factors for permanent pacemaker (PPM) post-cardiac surgery, alongside traditionally accepted determinants.Entities:
Keywords: mitral valve; pacemaker; valve surgery
Year: 2021 PMID: 34988330 PMCID: PMC8710354
Source DB: PubMed Journal: J Clin Transl Res ISSN: 2382-6533
Figure 1Patient selection and case–control matching
Patient characteristic
| AVR ( | MVR ( | ||
|---|---|---|---|
|
| 79.4% (490) | 20.6% (127) | |
| Male | 50.8% (249) | 52% (315) | 0.8 |
| Age | 66.8±12.4 | 66±11.3 | 0.5 |
| BMI | 27.4±4.8 | 26.8±5.6 | 0.2 |
| Hypertension | 62.7% (307) | 55.9% (71) | 0.2 |
| Diabetes mellitus | 11.6% (57) | 10.2% (13) | 0.7 |
| COPD | 19.4% (95) | 18.9% (24) | 0.9 |
| Chronic kidney disease | 3.1% (15) | 2.4% (3) | 0.7 |
| Neurological history | 13.1% (64) | 12.6% (16) | 0.9 |
| Ischemic heart disease | 11.2% (55) | 9.4% (12) | 0.6 |
| Non-sinus rhythm | 26.9% (132) | 40.9% (52) | 0.01 |
| - Atrial fibrillation | 25.9% (127) | 32.4% (41) | |
| - AVB I | 0.8% (4) | 8.5% (11) | |
| - AVB II (Mobitz 1) | 0.2% (1) | 0 | |
| Left ventricle EF | 0.01 | ||
| - >49% | 68.4% (335) | 59.9% (76) | |
| - 30–49% | 24.5% (120) | 37% (47) | |
| - <30% | 7.1% (35) | 3.1% (4) | |
| Active endocarditis | 5.9% (29) | 11.8% (15) | 0.02 |
| N previous heart surgery | 0.09±0.3 | 0.2±0.4 | 0.02 |
| Valve pathology | <0.001 | ||
| - Stenosis | 66.1% (324) | 3.1% (4) | |
| - Regurgitation | 16.1% (79) | 81.1% (103) | |
| - Mixed | 17.8% (87) | 15.7% (20) | |
| NYHA | 0.5 | ||
| - Class I/II | 50.2% (246) | 46.5% (59) | |
| - Class III/IV | 49.8% (244) | 53.5% (68) | |
| EuroSCORE II | 5±5.4 | 4.9±6.1 | 0.8 |
| Critical status | 2.7% (13) | 6.3% (8) | 0.04 |
| NCEPOD | 0.9 | ||
| - Elective | 74.1% (363) | 71.7% (91) | |
| - Expedite | 3.7% (18) | 3.2% (4) | |
| - Urgent | 21.4% (105) | 24.4% (31) | |
| - Emergency | 0.8% (4) | 0.8% (1) | |
| IABP | 4.9% (24) | 7.1% (9) | 0.3 |
| Operation time (min) | 251.1±57.4 | 268.7±63.5 | 0.01 |
Chronic kidney disease defined as GFR<60 ml/min/1.73 m2. Neurological history included previous stroke or known carotid artery stenosis. BMI: Body mass index; COPD: Chronic obstructive pulmonary disease; AVB I: First-degree atrioventricular block; AVB II: Second-degree atrioventricular block; EF: Ejection fraction; NCEPOD: National Confidential Enquiry into Patient Outcome and Death; IABP: Intra-aortic balloon pump.
Valve type and size in AVR and MVR
| AVR ( | MVR ( | ||
|---|---|---|---|
| Valve type, % ( | <0.001 | ||
| - ATS | 3.7 (18) | 5.7 (8) | |
| - Carboseal | 7.6 (37) | 11.3 (14) | |
| - Edwards | 17.7 (87) | 1.7 (2) | |
| - Hancock | 26.9 (132) | 37.3 (47) | |
| - Mitroflow | 1.4 (7) | 0 | |
| - On-X | 15.8 (77) | 15.8 (20) | |
| - Perceval | 1.6 (8) | 0 | |
| - St. Jude Medical | 3.7 (18) | 3.4 (4) | |
| - St. Jude | 0 | 24.8 (32) | |
| - Trifecta | 21.6 (106) | 0 | |
| Valve size, % ( | <0.001 | ||
| - 18–20 | 6.8 (33) | 0 | |
| - 21–23 | 59.8 (293) | 0 | |
| - 25 | 24 (118) | 10.4 (13) | |
| - 26–27 | 7 (34) | 19.4 (25) | |
| - 28–30 | 2.4 (12) | 25.5 (31) | |
| - 31–33 | 0 | 44.7 (58) |
Permanent pacemaker in the AVR and MVR groups
| AVR ( | MVR ( | ||
|---|---|---|---|
| Post-operative arrhythmias, % ( | <0.001 | ||
| - Atrial fibrillation | 51.4 (252) | 61.6 (78) | |
| - High degree AV block | 3.7 (18) | 3.1 (4) | |
| - Ventricular tachycardia | 0.7 (3) | 3.4 (4) | |
| PPM indication, % ( | 0.8 | ||
| - CHB | 3.7 (18) | 3.1 (4) | |
| PPM, % ( | 0.8 | ||
| - Yes | 3.7 (18) | 3.1 (4) | |
| - No | 96.3 (472) | 96.9 (123) | |
| PPM implantation, % ( | 0.4 | ||
| - Before day 5 | 0.4 (2) | 0 | |
| - After day 5 | 3.3 (16) | 3.1 (4) |
AV: Atrioventricular; CHB: Complete heart block.
Permanent pacemaker implantation: tAVR versus mAVR and tMVR versus mMVR
| PPM | ||
|---|---|---|
| AVR, % (n) | 0.6 | |
| - tAVR | 3.4 (11) | |
| - mAVR | 4.2 (7) | |
| MVR, % (n) | 0.8 | |
| - tMVR | 3.7 (2) | |
| - mMVR | 2.7 (2) |
tAVR: Tissue aortic valve replacement, mAVR: Mechanical aortic valve replacement, tMVR: Tissue mitral valve replacement, mMVR: Mechanical mitral valve replacement
Secondary outcomes
| AVR ( | MVR ( | ||
|---|---|---|---|
| Reopening | 4.5% (22) | 6.3% (8) | 0.4 |
| Myocardial infarction | 0.8% (4) | 3.2% (4) | 0.04 |
| Respiratory complications | 32.9% (161) | 38.6% (48) | 0.3 |
| Neurological complications | 9.2% (45) | 11.8% (15) | 0.4 |
| Renal complications | 9.8% (48) | 7.9% (10) | 0.5 |
| Wound complications | 1.4% (7) | 2.4% (3) | 0.5 |
| Infective complications | 5.5% (27) | 9.7% (11) | 0.2 |
| MOF | 7.9% (24) | 5.5% (5) | 0.6 |
| ITU stay (min) | 71±163.8 | 106.5±243.7 | 0.5 |
| Hospital stay (days) | 14.7±14.7 | 18.9±20.8 | 0.01 |
| In-hospital mortality | 4.1% (20) | 3.9% (5) | 0.9 |
MOF: Multiple organ failure; ITU: Intensive therapy unit.